Olema Pharmaceuticals (OLMA) Operating Leases (2021 - 2025)

Olema Pharmaceuticals (OLMA) has reported Operating Leases for 5 consecutive years, with $69000.0 the latest figure, recorded in Q4 2025.

• In Q4 2025, Operating Leases fell 73.15% year-over-year to $69000.0; the TTM figure through Dec 2025 stood at $69000.0 (down 73.15% YoY), while the FY2025 annual figure was $69000.0, down 73.15% from the prior year.
• Operating Leases slipped to $69000.0 in Q4 2025 per OLMA's latest filing, from $310000.0 in the prior quarter.
• Across five years, Operating Leases topped out at $2.4 million in Q4 2021 and bottomed at $69000.0 in Q4 2025.
• Historically, Operating Leases has averaged $1.1 million across 5 years, with a median of $1.2 million in 2023.
• Annual changes were most pronounced in 2023 — Operating Leases slipped 2.69% — and 2025, when it plunged 89.32%.
• Olema Pharmaceuticals' Operating Leases stood at $2.4 million in 2021, then slumped by 34.27% to $1.5 million in 2022, then dropped by 7.81% to $1.4 million in 2023, then plunged by 82.02% to $257000.0 in 2024, then tumbled by 73.15% to $69000.0 in 2025.
• Business Quant data shows OLMA's Operating Leases at $69000.0 in Q4 2025, $310000.0 in Q3 2025, and $602000.0 in Q2 2025.